Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 9/20 | 0.43 |
| ▸ | MAPT | P10636 | 7/20 | 0.42 |
| ▸ | HTT | P42858 | 6/20 | 0.42 |
| ▸ | MITF | O75030 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.40 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.40 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.40 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.40 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8884170 | 0.81 | GRIN2D (0.41) | LMNAMAPTKMT2ANPC1RAB9A | |
| SCHEMBL10415524 | 0.81 | ALDH1A1 (0.46) | LMNAMAPTHTTMITFKMT2A | |
| SCHEMBL28342145 | 0.81 | ALDH1A1 (0.42) | LMNAMAPTHTTMITFKMT2A | |
| SCHEMBL30600835 | 0.81 | GRIN2D (0.41) | LMNAMAPTKMT2ANPC1RAB9A | |
| SCHEMBL30546881 | 0.81 | GRIN2D (0.41) | LMNAMAPTHTTMITFKMT2A | |
| SCHEMBL23647925 | 0.81 | GRIN2D (0.41) | LMNAMAPTHTTMITFKMT2A | |
| SCHEMBL9131751 | 0.80 | ALDH1A1 (0.41) | LMNAMAPTHTTMITFKMT2A | |
| SCHEMBL2086204 | 0.79 | MAPT (0.44) | LMNAMAPTHTTMITFKMT2A | |
| SCHEMBL1366268 | 0.79 | GRIN2D (0.40) | LMNAMAPTHTTKMT2ANPC1 | |
| SCHEMBL1366985 | 0.79 | GRIN2D (0.40) | LMNAMAPTKMT2ATDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 168 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114773207-A | Method and catalyst for selective nitro reduction hydrogenation reaction by using micro packed bed | 南京药石科技股份有限公司 | 2022-07-22 | — | — | CN | claimed |
| US-12459927-B2 | Plasma kallikrein inhibitors | MERCK SHARP & DOHME LLC (US) | 2025-11-04 | — | — | US | disclosed |
| WO-2025101780-A1 | PHARMACOLOGICAL CORRECTORS OF RHODOPSIN AND USES THEREOF | OCTANT, INC. (US) | 2025-05-15 | — | — | WO | disclosed |
| EP-4522618-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES COMPOUNDS AS HPK1 INHIBITORS | Merck Patent GmbH (DE) | 2025-03-19 | — | — | EP | disclosed |
| EP-4090661-B1 | QUINOXALINE DERIVATIVES AS MODULATORS OF THE GLUCOCORTICOID RECEPTOR | GRUENENTHAL GMBH (DE) | 2025-03-12 | — | — | EP | disclosed |
| CN-115989224-B | Plasma kallikrein inhibitors | 默沙东有限责任公司 | 2025-02-25 | — | — | CN | disclosed |
| US-12145925-B2 | Phthalazine derivatives as inhibitors of PARP1, PARP2, and/or tubulin useful for the treatment of cancer | ATLASMEDX, INC. (US) | 2024-11-19 | — | — | US | disclosed |
| US-20240336629-A1 | Tricyclic Derivatives Useful As PARP7 Inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-10-10 | — | — | US | disclosed |
| CN-114401964-B | Compound with BRD4 inhibitory activity, preparation method and application thereof | 上海海和药物研究开发股份有限公司 | 2024-10-01 | — | — | CN | disclosed |
| US-20240150343-A1 | COMPOUND HAVING BRD4 INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND USE THEREOF | HAIHE BIOPHARMA CO., LTD. (CN) | 2024-05-09 | — | — | US | disclosed |
| US-5608068-A | Process for the preparation of imidazopyridine derivatives and intermediates | EISAI CO., LTD. (JP) | 1997-03-04 | — | — | US | disclosed |
| US-5587504-A | Sulfonyloxy-biphenylcarboxylic ester derivatives which are intermediates | EISAI CO., LTD. (JP) | 1996-12-24 | — | — | US | disclosed |
| US-5583229-A | Process for the preparation of imidazopyridine derivatives | EISAI CO., LTD. (JP) | 1996-12-10 | — | — | US | disclosed |
| US-5559236-A | Intermediates for substituted biphenylmethylmidazopyridine angiotensin II antagonists | EISAI CO., LTD. (JP) | 1996-09-24 | — | — | US | disclosed |
| US-5557002-A | Process for the preparation of biphenyl containing intermediates useful in making angiotensin II receptor antagonists | EISAI CO., LTD. (JP) | 1996-09-17 | — | — | US | disclosed |
| US-5554757-A | Process for the preparation of imidazopyridine derivatives, and intermediates therefore | EISAI CO., LTD. (JP) | 1996-09-10 | — | — | US | disclosed |
| US-5453512-A | Bromination of acylaminopyridine with 2-acylaminopyridinium hydorbromide | ICHIKAWA GOSEI CHEMICAL CO., LTD. (JP) | 1995-09-26 | — | — | US | disclosed |
| EP-0627433-A1 | PROCESS FOR PRODUCING IMIDAZOPYRIDINE DERIVATIVE AND INTERMEDIATE | Eisai Co., Ltd. (JP) | 1994-12-07 | — | — | EP | disclosed |
| US-5290943-A | Halogenation of pyridine compound | ICHIKAWA GOSEI CHEMICAL CO., LTD. (JP) | 1994-03-01 | — | — | US | disclosed |
| EP-0530524-A1 | Method of producing 2-amino-3-nitro-5-halogenopyridine | ICHIKAWA GOSEI CHEMICAL CO., LTD. (JP) | 1993-03-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240150343-A1 | COMPOUND HAVING BRD4 INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND USE THEREOF | BRD4, BICRA, BET1 | LMNA 1021/4885MAPT 2296/4885HTT 1127/4885 |
| US-12145925-B2 | Phthalazine derivatives as inhibitors of PARP1, PARP2, and/or tubulin useful for the treatment of cancer | PARP2, PARP12, PARP1 | LMNA 1010/4885MAPT 118/4885HTT 1662/4885 |
| US-12459927-B2 | Plasma kallikrein inhibitors | KLKB1, SERPINE1, KLK5 | LMNA 2426/4885MAPT 781/4885HTT 3727/4885 |
| US-20240336629-A1 | Tricyclic Derivatives Useful As PARP7 Inhibitors | PARP1, PARP2, PARP11 | LMNA 239/4885MAPT 2281/4885HTT 1740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.